SCHEMBL29355019

SCHEMBL29355019

CC(C)[C@H](NC(=O)CN)C(=O)NCC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
PTGS2 P35354 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ECE1 P42892 1/20 0.46
MME P08473 2/20 0.41
ACE P12821 2/20 0.41
CPA1 P15085 1/20 0.41
ACE2 Q9BYF1 1/20 0.41
ITGB3 P05106 2/20 0.41
ITGB1 P05556 2/20 0.41
ITGAV P06756 2/20 0.41
ITGA5 P08648 2/20 0.41
CTSC P53634 1/20 0.40
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
PTGS1 P23219 1/20 0.36
GSTK1 Q9Y2Q3 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27739908 1.00 LMNA (0.47) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL27739903 1.00 LMNA (0.47) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL29980033 0.92 LMNA (0.43) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL30569806 0.91 ALDH1A1 (0.42) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL29566626 0.88 ALDH1A1 (0.46) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL7200312 0.86 KMT2A (0.38) LMNAECE1CTSCCTSSCTSK
SCHEMBL7200310 0.86 KMT2A (0.38) LMNAECE1CTSCCTSSCTSK
SCHEMBL22892432 0.85 MME (0.53) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL22892480 0.85 MME (0.53) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL28706003 0.85 MME (0.53) LMNAALDH1A1MAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4017541-A1 IMMUNE TOLERANT ELASTIN-LIKE RECOMBINANT PEPTIDES AND METHODS OF USE University of Utah Research Foundation (US) 2022-06-29 EP claimed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
CN-118792318-A Application of nucleic acid molecule and OsCTS protein coded by same in regulation and control of rice seedling stage cold resistance 中国农业大学 2024-10-18 CN disclosed
WO-2023064887-A1 MECHANOCHEMICAL DYNAMIC THERAPY FOR FOCAL CANCER TREATMENT THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-04-20 WO disclosed
US-20230109312-A1 NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IGENICA BIOTHERAPEUTICS, INC. 2023-04-06 US disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 US disclosed
US-11229711-B2 Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use Magenta Therapeutics, Inc. (US) 2022-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP LMNA 1538/4885ALDH1A1 3596/4885MAPT 3330/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD LMNA 3184/4885ALDH1A1 4110/4885MAPT 4191/4885
US-20230109312-A1 NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SDCBP, DCLRE1A, BCR LMNA 1207/4885ALDH1A1 2431/4885MAPT 1441/4885
US-11229711-B2 Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use CLSPN, SDCBP, DCLRE1A LMNA 832/4885ALDH1A1 2503/4885MAPT 771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.